When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Autism spectrum disorder

Última revisão: 24 Sep 2025
Última atualização: 20 Nov 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • language delay or regression
  • verbal and nonverbal communication impairment
  • social impairment
  • repetitive, rigid, or stereotyped interests, behavior, or activities
Detalhes completos

Outros fatores diagnósticos

  • placid or very irritable as a baby
  • feeding difficulties
  • unusual posturing
  • motor stereotypies
  • sensory interests or difficulties
  • evidence of other neurodevelopmental disorder
  • macrocephaly
Detalhes completos

Fatores de risco

  • male sex
  • positive family history
  • gestational valproate exposure
  • genetic variants
  • karyotype (chromosomal) abnormalities
  • increasing parental age
  • prematurity
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • ASD screening tests
  • Childhood Autism Rating Scale (CARS)
  • Modified Checklist for Autism in Toddlers (M-CHAT)
  • Childhood Autism Screening Test (CAST)
Detalhes completos

Tests to avoid

  • hair analysis
  • heavy metal urine test and mineral panel
Detalhes completos

Investigações a serem consideradas

  • diagnostic questionnaires (e.g., Autism Diagnostic Interview-Revised [ADI-R]; Developmental, Dimensional, and Diagnostic Interview [3di]; Diagnostic Interview for Social and Communication Disorders [DISCO])
  • Autism Diagnostic Observational Schedule (ADOS)
  • skin examination with Wood lamp
  • genetic testing
  • EEG
  • MRI brain
  • audiology
  • specific testing for genetic disorders (e.g., MECP2 deletion)
Detalhes completos

Algoritmo de tratamento

CONTÍNUA

preschool children ages 12 months to 5 years (or equivalent developmental age)

school-age children ages 5 to 18 years (or equivalent developmental age)

adults

Colaboradores

Autores

Jeremy Parr, MB ChB, MRCPCH, MD

Professor/Honorary Consultant

Population Health Sciences Institute

Newcastle University

Newcastle upon Tyne

UK

Declarações

JP is a director and shareholder in XRTherapeutics, which offers virtual reality intervention for situation specific anxiety and phobia for people with autism and other conditions. He is named on a patent owned by Third Eye Neurotech and would receive royalties from this, through Newcastle University. JP previously chaired Research Autism's Scientific Advisory Committee; was an expert advisor to the National Autism Project; sits on the Autistica Discover Steering Committee; currently chairs the Autistica Physical Health and Ageing Research Group; and currently chairs the British Academy of Childhood Disability Strategic Research Group. He has not received payment for any of this activity. JP works for the UK NHS and sees children and young adults on the autism spectrum to give advice about diagnosis and treatments/interventions. JP runs research programs focused on autism from Newcastle University, and has received grants and published research papers in that context. JP is an author of a number of references cited in this topic.

Marc Woodbury-Smith, MB ChB, PhD, MRCPsych
Marc Woodbury-Smith

Clinical Senior Lecturer/Honorary Consultant

Biosciences Institute

Newcastle University

Newcastle upon Tyne

UK

Associate Investigator

Centre for Applied Genomics

Hospital for Sick Children

Toronto

Canada

Declarações

MWS has received consultation fees from Servier Pharmaceuticals in connection with a clinical trial on which he was national co-ordinator (2018-2019). MWS is the co-author of references cited in this topic.

Revisores

Robert Findling, MD, MBA

Chair

Department of Psychiatry

Virginia Commonwealth University

Richmond

VA

Declarações

RF declares that he has acted as a consultant for, and/or has received honoraria or research support from the following: Acadia, Adamas, Aevi, Afecta, Akili, Alkermes, Allergan, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Axsome, Daiichi-Sankyo, Emelex, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Kempharm, Luminopia, Lundbeck, MedAvante-ProPhase, Merck, MJH Life Sciences, NIH, Neurim, Otsuka, PaxMedica, PCORI, Pfizer, Physicians Postgraduate Press, Q BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Sunovion, Supernus Pharmaceuticals, Syneos, Syneurx, Takeda, Teva, Tris, and Validus.

Michael Absoud, FRCPCH, PhD

Consultant in Paediatric Neurodisability

Joint Head of Service

Children’s Neurosciences

Reader in Paediatric Neurosciences

Evelina London Children’s Hospital

Department of Women and Children’s Health

King’s College

London

UK

Declarações

MA declares that he has no competing interests.

Grant Stewart, BA Hons

Consumer Health and Multimedia Manager

British Medical Journal (BMJ)

London

UK

Declarações

GS declares that he is an employee of BMJ.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Levy SE, Mandell DS, Schultz RT. Autism. Lancet. 2009 Nov 7;374(9701):1627-38.Texto completo  Resumo

Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autistic spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006 Jul 15;368(9531):210-5. Resumo

Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020 Jan;145(1):e20193447.Texto completo  Resumo

Anagnostou E, Zwaigenbaum L, Szatmari P, et al. Autism spectrum disorder: advances in evidence-based practice. CMAJ. 2014 Apr 15;186(7):509-19. Resumo

National Institute for Health and Care Excellence. Autism spectrum disorder in adults: diagnosis and management. June 2021 [internet publication].Texto completo

Baird G, Cass H, Slonims V. Diagnosis of autism. BMJ. 2003 Aug 30;327(7413):488-93.Texto completo  Resumo

Le Couteur A, Haden G, Hammal D, et al. Diagnosing autistic spectrum disorders in pre-school children using two standardised assessment instruments: the ADI-R and the ADOS. J Autism Dev Disord. 2008 Feb;38(2):362-72. Resumo

Parr J. Autism. BMJ Clin Evid. 2010 Jan 7;2010:0322.Texto completo

National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: support and management. June 2021 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Diagnósticos diferenciais

    • Other causes of disordered development/learning difficulties/intellectual disability, or another neurodevelopmental disorder
    • ADHD
    • Social (pragmatic) communication disorder
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR)
    • Autism spectrum disorder in under 19s: support and management
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Autism spectrum disorder: information for parents - What is autism spectrum disorder?

    Autism spectrum disorder: information for parents - Support strategies

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal